-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MXNijvv06sIfv4egPm+whvIWsotIIf8GV26uPi1KhiMuOvrixsVZUslIQ+3laUe9
 Jp1r3v6E5TkZpffwPBM5eA==

<SEC-DOCUMENT>0001144204-08-056503.txt : 20081007
<SEC-HEADER>0001144204-08-056503.hdr.sgml : 20081007
<ACCEPTANCE-DATETIME>20081007163357
ACCESSION NUMBER:		0001144204-08-056503
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20081007
FILED AS OF DATE:		20081007
DATE AS OF CHANGE:		20081007

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		081112536

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v128249_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vfvf-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      month of October 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font face="Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" align="left" noshade size="2" width="100%">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
      by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated October 7,
      2008
      is hereby incorporated by reference into the registration statements on Form
      F-3
      (File No. 333-141529, File No. 333-147024 and File No. 333-153055) filed by
      XTL
      Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March
      23,
      2007 , October 30, 2007 and August 15, 2008, respectively, and the registration
      statements on Form S-8 (File No. 333-148058 and File No. 333-148574) filed
      by
      XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on
      December 14, 2007 and January 18, 2008, respectively.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"> <IMG SRC="logo.jpg"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals Announces Completion of the Bicifadine Phase 2b Study for
      Diabetic Neuropathic</strong></font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>
      Pain</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York, October 7, 2008</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      - XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) announced today that the
      last
      patient randomized into the Bicifadine Phase 2b clinical trial for the treatment
      of diabetic neuropathic pain has completed the study. This milestone officially
      marks the completion of this randomized, double-blind, placebo-controlled Phase
      2b clinical trial which enrolled 351 patients at approximately 40 sites in
      the
      United States, Germany, Israel and India. The Company expects to report top-line
      results from this study within 6-8 weeks. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bicifadine
      is a first-in-class triple reuptake inhibitor for the treatment of diabetic
      neuropathic pain. Bicifadine&#8217;s main effect is as a serotonin and norepinephrine
      reuptake inhibitor with a moderate effect on dopamine reuptake inhibition,
      believed to be potentially complementary in treating neuropathic pain. The
      Phase
      2b trial is aimed at demonstrating the efficacy of Bicifadine for the treatment
      of diabetic neuropathic pain, using a study design that is similar to the
      successful registration trials of Cymbalta&#174;, a dual-reuptake inhibitor of
      serotonin and norepinephrine that is approved for this indication, and other
      approved agents for neuropathic pain. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Phase
      2b trial is a randomized, double-blind, placebo-controlled study comparing
      200mg
      3x/day (tid) and 400mg 3x/day (tid) of Bicifadine versus placebo, with a 1:1:1
      randomization between the three arms, in patients with diabetic neuropathic
      pain. Following randomization, all patients entered a 2-week titration period
      to
      allow them to gradually escalate up to their target treatment dose. This was
      followed by a 12-week steady-state treatment period at the target treatment
      dose. The primary endpoint of the study is to compare the efficacy of each
      of
      the two active doses of Bicifadine (200mg tid and 400mg tid) versus placebo
      in
      reduction of pain associated with diabetic neuropathy, at baseline (at the
      time
      of randomization) versus week 14 (week 12 of the steady-state phase). Pain
      is
      measured based on a 24-hour pain rating using the 11-point Pain Intensity
      Numeric Rating Scale (formerly referred to as the LIKERT scale).</font></div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" align="left" noshade size="2" width="100%">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div><br></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">"The
      completion of the Bicifadine Phase 2b clinical trial is an important and
      significant milestone for XTL," stated Ron Bentsur, CEO of the Company, who
      continued, "We are grateful for the dedication of all the investigators who
      participated in the study, and we look forward to reporting top-line data from
      the study later this quarter."</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      in-licensed the worldwide rights to Bicifadine from Dov Pharmaceutical, Inc.
      (NASDAQ OTC: DOVP) in January 2007.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
      for the treatment of diabetic neuropathic pain and HCV. XTL is developing
      Bicifadine, a triple reuptake inhibitor of serotonin, norepinephrine and
      dopamine, which is currently in a Phase 2b study for the treatment of diabetic
      neuropathic pain. XTL has out-licensed its novel pre-clinical HCV small molecule
      inhibitor program. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock
      Exchanges (NASDAQ: XTLB; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Contact:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
      Statement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
      of the statements included in this press release, particularly those
      anticipating future clinical and business prospects for our clinical compound
      for neuropathic pain, Bicifadine, the likelihood of successful results from
      a
      clinical trial with Bicifadine, operating strategies and similar matters, may
      be
      forward-looking statements that involve a number of risks and uncertainties.
      For
      those statements, we claim the protection of the safe harbor for forward-looking
      statements contained in the Private Securities Litigation Reform Act of 1995.
      Among the factors that could cause our actual results to differ materially
      are
      the following: our ability to obtain positive trial results from the Phase
      2b
      clinical trial of Bicifadine, raise the funding necessary for our future
      operations, and other risk factors identified from time to time in our reports
      filed with the Securities and Exchange Commission, including our annual report
      on Form 20-F filed with the Securities and Exchange Commission on March 27,
      2008. Any forward-looking statements set forth in this press release speak
      only
      as of the date of this press release. We do not intend to update any of these
      forward-looking statements to reflect events or circumstances that occur after
      the date hereof. This press release and prior releases are available at
      http://www.xtlbio.com. The information in our website is not incorporated by
      reference into this press release and is included as an inactive textual
      reference only.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" align="left" noshade size="2" width="100%">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div><br></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:&#160;October
              7, 2008</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Bill
              Kessler</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Bill
              Kessler</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Director
              of Finance</font></td>
          </tr>

      </table><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!-`.<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BLW7M<M
M/#NDRZG?B7[+$1YC1(7*@G&2!VS7'_\`"Z?!O_/Q>?\`@*U7&G.2O%$N<8NS
M9VNK:K9:)ID^HZA.L%M"NYW;]`/4GH!7E+_'RR^V*$T.Y-M@[F,J[\]L#IC\
M:/B+XCM?&WPXN+S0+F1K:QO$^V1.A5F7'!QZ9(.?]D^E>&UV8?#1E%N>YRUZ
M\HM<NQ]AZ#KEEXCT:WU33W9K><$C<,$$'!!'J""*TJ\7^%FN6/A#X<W6K:R[
MPVEQJ16`JI8R'8H.`/=&_P"^373?\+I\&_\`/Q>?^`K5S3HR4FHJZ-XU8\J<
MG8]"HKE_^$_T/_A%#XE+W"Z;YGEAV@8,3G'"]2,]ZQ?^%T^#?^?B\_\``5JE
M4IO9%.I!;L]"HKSW_A=/@W_GXO/_``%:C_A=/@W_`)^+S_P%:CV-3^5B]K#N
M>A45Y[_PNGP;_P`_%Y_X"M1_PNGP;_S\7G_@*U'L:G\K#VL.YZ%17GO_``NG
MP;_S\7G_`("M6OX<^(OA_P`5:FVG:7+</<+$9B)(2@V@@'D_[PH=*:5VAJI!
MNR9U=%%%9EA117-VGCG1;Z_BLH))S-*^Q08B!GZU<:<YW<5>QE4K4Z;2F[7V
M.DHHHJ#4****`"BN7MOB!H5W<PV\4DYDF=8T!B(Y)P/YUU%7.G.GI-6,J5>G
M53=.5[!1114&H4444`%%%%`$-Y:07UG-:7,8D@F0QR(>C*1@C\J^4O&WA:7P
MAXGN-,8N]L?WEK*V,R1'IG'<=#TY&<8(KZSKB_B;X1_X2SPPZP#_`$^SS-;X
M!.X@<IQZC]<5TX:K[.5GLS#$4N>.FZ/"_AUXBC\/>*8Q=HDFGWR_9;M'&5V,
M>"1@YP<?AFO:S\'_``9)J`O!82B/DFW6=A$Q.,'&<\>@..>G2OF<CJ",'H0:
M]9M/BH\'PF?3Q-_Q/(F%C&2<DQ$$B7MT4%>-WS!2?O"NO$4YMJ5-[Z'-0J1L
MXSZ&!\4?$T6L^(?[-T\PKI&F9BMXX4"KOP-YXZ\C`[8'N<X7A#PQ=>+_`!%#
MI5LZQJ09)Y6&1'&,9;'<\@`>I'3K6&`6(`!9B<#N2:^F_AAX,7PMX<62Z@"Z
MI=@/<,5^9!_#']!_,FG5FJ%.RW)IQ=:I=[$'Q-T5E^&3Z7I%D[)"T*1P0J6(
M4,/Q/UKP+_A%/$/_`$!+_P#[\-7U[17'3Q,J<;)'54P\9N[9\>W/AW6K.W>X
MN=)O(84&7D>$A5'N:S*^J/B=_P`DWUS_`*X#_P!"6OE>N[#U75C=G'7I*F[(
MT;30-8O[9;FTTN[G@;(62.(LIP<'!^M3'PIXA`S_`&)?_P#?AO\`"OH;X0?\
MDOTC_>G_`/1\E=Q7//%RC)JQO'"Q<4[GQ=/!-:SO!<1/%-&=KHXP5/H17HWP
M-_Y'Z?\`[!\G_HR.N:^(7_)0]>_Z^V_D*Z7X&_\`(_3_`/8/D_\`1D==%9WH
MM^1A25JR1]%T445Y!Z@&O#/#7_(Y6'_7U_4U[D>E>'>&O^1RL/\`KZ_J:]/+
M_@J>G^9X6;_Q:'K_`)'N5%<)X@^(T%C.UMI4274J\-,S?NP?08Y;OW&/>L1?
MBAJX==UE8E<C("N"1WP=U<\,#7G'F2.NIFV%ISY'(]6HKG?#?B^Q\19B0&WN
MU&6@D(.1ZJ>X_`'VKH3TX.*YJD)0?+-69W4JL*L5.F[H\PTSX<:O9ZE974MS
M9%89HY'"NY)"L"<?+[5Z>.E>?V'Q,:^O[6U_LC89Y4CW?:<A=Q`_N<]:]`!X
MZUTXMUG)>V6IQ9='"J,OJSNKZ[_J+17->(?&NG:"S0<W-X/^6,9'R_[Q_A_4
M\CBN.?XHZMO8I9V*KD[0P<D#MD[N:FE@ZU17BM"J^98:A+EE+7RU/5J*\WTO
MXH,9BFK6:K&3Q);`_+]5).?P/X&O0;.]MM0M([JTF2:"095U/!J*N'J4OC1M
MAL91Q*O2=R>BBBL3I"@]***`/G;XQ>#/[#UL:W91*NGZ@^'1,`138Y`'HP!;
MZ[O:O,Z]6^,_C,ZEJO\`PC=E+FTLG#7+*W^LF_N\'D+GO_%G^[7E->QA^;V:
MYCRJ_+SOE/4_@YX(&KZD^O:E;;K"U.+99%&V:7/)]PN/3&2.?E(KZ"KYK^$W
MC,>&?$)L;R0C3-0(1N0!%+D!7.>@QD'\#VKZ4KAQ:E[3WOD=N&<>3W0HHHKE
M.@Y+XG?\DWUS_K@/_0EKY7KZH^)W_)-]<_ZX#_T):^5Z]+!?`_4\_%_$CZ=^
M$'_)+](_WI__`$?)7<5P_P`(/^27Z1_O3_\`H^2NXKAJ_P`27J=M/X%Z'R?\
M0O\`DH>O?]?;?R%=+\#?^1^G_P"P?)_Z,CKFOB%_R4/7O^OMOY"NE^!O_(_3
M_P#8/D_]&1UZ53^!\C@A_'^9]%T445Y)Z0AZ5\\&62"\:6)V217)5E.".:^A
MSTKY^M(?M&M0PE=P>X"D'N-W->KECMS_`"_4^>SY-NDEW?Z'I7AGP'81:;'<
M:M`+BZF7<4<Y5`<8'!Y/O[UKS^"/#TL#QKIL<>[^*,D,/H:Z!5"J%`P!P!Z4
MM<$\15E+FYF>O3P5"G35-15O0\)UC3+SPOKIB261'C.^"=>"R]B/Y&O8]"U0
M:OHMK>#&Z1!O'HPX/ZUPOQ2M@MWIUUNY='CVXZ8(.?\`QZM7X97/FZ!<08(\
MF<\XZ[@#7=BG[;"QJO<\G`+ZOCZF'C\.YYQX?_Y&#2_^OJ'_`-#%>O\`BO7/
M["T*6:/'VB4^7"/]H]_P'->0>'_^1@TO_KZA_P#0Q7:?%&=PVFVX/[L^8Y'O
MP/ZFNC%4U4Q-.+V.3`5G1P-6<=[_`)Z'-^%_#\OB;5W625A"A\VXD.2S9/0'
MU)SU]Z]9M/#.BV47EPZ=;X(P2Z!B?Q-87PTLA!X<>Z*C?<S,0W<JOR@?F&_.
MNSKAQN(E*HXIV2/5RO!TX4%4DKREK<X/Q7X#M9=/:ZT:W6&YA!8PJ<+*O4]>
MC>GY5S?@/Q'+I>KQ6$KEK.Z;9M)_U;GHP^IX/USVKU\C(Q7@VO6Z6/B:^ACS
MLCN#C/US71@YNO3E1J:G'F=-82K#$T=-=3WH=**9$XEB209PRAAGWHKR3Z).
M^H^N*^)GC`>$_#3^0^-0O-T-L`>5..7ZYX'?UQ76WU[;Z;8SWMW(([>!#)(Y
M[`#)KY2\:>*9O%_B6XU-PZ0<1VT+D'RXQT''<G+'KR>N`*Z,-2]I.[V1A7J\
MD=-V<_ZDGWKU>#X422?"MM3\MAKCG[8$8XQ"`?W?/<J=WUP.U<[\,/"7_"5>
M*D\]<V%EMGN,@X;GY4_$C\@:^GPH50H```Q@#BNK$XAPDHQ.?#T5).4CXJR"
M,BOI#X2>,_\`A(M!.G7LH;4K!0K$@`R1=%;`ZXX!_#UKRWXK^$CX<\4O=6T)
M33K\F6(J/E1_XDX&!SR!Z'ZUS/AGQ#>>%O$%KJUFS;HFQ+&&VB:,_>0^Q^AP
M0#U`K2I%5Z=U\C.G)T:EF?7U%4]*U2TUG3+?4+&82VTZ!T8?R/H?:KE>3L>F
M<E\3O^2;ZY_UP'_H2U\KU]4?$[_DF^N?]<!_Z$M?*]>E@O@?J>?B_B1]._"#
M_DE^D?[T_P#Z/DKN*X?X0?\`)+](_P!Z?_T?)7<5PU?XDO4[:?P+T/D_XA?\
ME#U[_K[;^0KI?@;_`,C]/_V#Y/\`T9'7-?$+_DH>O?\`7VW\A69H?B#5/#=\
MU[I%W]EN6C,1D$:/\I()&&!'517J.+G1Y5V/.4E&KS/N?8=%?+O_``MGQU_T
M'V_\!(/_`(W1_P`+9\=?]!]O_`2#_P"-UQ?4JG='7];IGU">E>#:-<"T\3V<
M[#(2Z&?^^L5RQ^+/CK!_XG[?^`D'_P`;K61W9E<,?,.&RO!SUR*[\%AY04U+
MK_P3P\YKJ4J4H]&_T/HVBN-\->.]/OK)8M1E2TO(\*=Y^63C[P/X<@_UK8U#
MQ7HNGQ%Y;^)FVY"1-N8_3%>7+#U8RY7%W/<ABZ$X>T4E;U.*^*5R6OM/MMHP
MD;29^IQ_[+6[\-[?R?#!E*D&:9FR5QD#`_&O/=0O+WQ=XB#1QDRSMLAB)'R*
M.V?89)->SZ5I\6E:3;64.2D*!<DDY/<\^IR:[<7^ZPT:+W/)R_\`VC&U,2OA
MV7]>AX;X?_Y&#2_^OJ'_`-#%=I\487+:;.!^['F(3[G!_I7%^'_^1@TO_KZA
M_P#0Q7K_`(LT3^W=!EA0?Z1"3+"0.2P[?B.*Z<545/$TY2VU./`476P-6$=[
M_EJ9?PTO?/\`#DEJS@M;3L`H'(5OF'ZEJ[2O$/"VOR>&M79Y4<P.?+N(^A&#
MZ>H/]17K-IXGT6]B,D.HP8498,VTC\#7#C</.-1R2NF>KE>,ISH*G)VE'34U
M2<#->#:_<1WOB:^GC/[M[@X)],XKT#Q7X\M+>Q-KI$Z3W,H(,J\K$/7W/M7,
M^`O#TFIZQ'?31L+.U._=V>08VK_4_3'>NC!P="$JU30X\SJ+%U88:CKKJ>NQ
M((H4C'1%"C\**?17D[GT6QS'CCPM=^+]&33(-7;3H6?=/B#S/-`Z*?F7`SS7
MG7_#/S?]#0/_``7_`/VVO;**UA7J05HLSE2A-WDCG/!/A&#P9X?738IA<2M(
MTLUP(RAE8G@[<G&%"C@]L]S71T45FVY.[+225D8'C#PK:^,/#TVE7,AA8L)(
M9U4,8I!T;!Z\$@CC()Y'6O,O^&?F_P"AH'_@O_\`MM>V45I"M."M%D3I0F[R
M1R7@/P==^"]/GL)-86_M7?S(U-L8S$QZ\[V!!XXP.>]=;116<I.3NRTE%61D
M>*-$_P"$D\-7VC_:/LWVI`GF[-^WD'ID9Z>M>5?\,_-_T-`_\%__`-MKVRBM
M(5IP5HLB=*$W>2,/P?X=_P"$4\+V>B_:OM7V<R'SO+\O=N=G^[DXQNQU[5N4
M45FVV[LM*RLCR;Q%\%#KWB*_U7_A(?(^URF3ROL6_;GMGS!G\A69_P`,_-_T
M-`_\%_\`]MKVRBMEB:J5DS)T*;=VCQ/_`(9^;_H:!_X+_P#[;1_PS\W_`$-`
M_P#!?_\`;:]LHI_6JO?\@^KT^QXF?V?6(Q_PE`_\%_\`]LKK])^&W]EZG:WC
M:J)A`P8QFVQN]L[C7>T4?6JUG&^_H9SP5"<E*4=5MN>?ZU\-(KJZEN=,NEM]
M^#]GD3*`]\,.0.^,'GT'`RX/A;J33`3W]I'%W:,,Y_(@?SKU2BM(XZO&-KG/
M/*<).7,X_B87A[PI8>'H\Q#SKDCYIY%&[W`]!QTK<(XXI:*Y9SE-\TG=G?3I
M0I14(*R1Y_8?#(V-_:W?]K[_`")4DV?9L;MI!QG?QTKOP,"EHJZM:=5IS=S/
M#X6EATU25KG->(O!6G:\6G&;6]/_`"WC7(;_`'E[_H?>N0G^%VIB8B"^M)(L
M#:TFY&/KP`<?G7JE%:4L76IJT7H85\MPU>7-*.O=:'G6F_"Y5=)-4O\`>HSN
MAMUP#SQ\YYQ^`^M=_:6EO8VT=M;1+%#&NU47L*FHJ*M>I5^-W-</A*.'5J4;
(!1116)TG_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
